Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: A 16 week, double-blind, placebo-controlled trial

Annals of Pharmacotherapy

Volumn 40, Issue 10, 2006, Pages 1717-1723

  Anderson, James W ^a   Schwartz, Susan M ^b   Hauptman, Jonathan ^c   Boldrin, Mark ^d   Rossi, Maureen ^d   Bansal, Vidhu ^e   Hale, Cecilia A ^e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b GLAXOSMITHKLINE   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Hoffmann La Roche Ltd   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Orlistat; Overweight; Weight loss

Indexed keywords

GLUCOSE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TETRAHYDROLIPSTATIN;

ABNORMAL FECES; ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION DISORDER; DEFECATION URGENCY; DIASTOLE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FATTY STOOL; FEMALE; FLATULENCE; FLATUS WITH DISCHARGE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED DEFECATION; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; LOW CALORY DIET; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PATIENT EDUCATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SYSTOLE; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BODY MASS INDEX; BODY WEIGHT; DIET, REDUCING; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; LIFE STYLE; MALE; MIDDLE AGED; OVERWEIGHT; TIME FACTORS; WEIGHT LOSS;

EID: 33749638780     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H234     Document Type: Article

References (25)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-7.
2. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
3. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995; 273:461-5.
4. McGill HC, McMahan CA, Herderich EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 2002;105:2712-8.
5. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Library 2003;1-66.
6. The practical guide. Identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: National Institutes of Health, NIH publication no. 00-4084, October 2000.
7. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr 2004;79:529-36.
8. De Smet PAGM. Herbal medicine in Europe - relaxing regulatory standards. N Engl J Med 2005;352:1176-8.
9. Final minutes of the Joint Meeting of the Nonprescription Drugs and the Endocrinologic & Metabolic Drugs Advisory Committee, January 23, 2006. www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4201M.pdf (accessed 2006 Aug 21).
10. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000;20:270-9.
11. Rossner S, Sjostrom L, Noack R, Meinders E, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.
12. Jacob S, Torgerson J. Orlistat treatment beneficial in both primary care and tertiary care settings. Presented at: European Congress of Obesity, Athens, Greece, June 1-4, 2005.
13. Data on file. Hoffman LaRoche. World-wide orlistat postmarketing surveillance data from June 1998 to January 31, 2006.
14. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal K. Orlistat in the long-term treatment of obesity in the primary care setting. Arch Fam Med 2000;9:160-7.
15. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res 2001;9(suppl 4):228S-33S.
16. Anderson JW, Kendall CWC, Jenkins DJA. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331-9.
17. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
18. Hubert HB, Feinleib M, McNamara PM, Castelli WC. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:969-77.
19. Calle EE, Thun MM, Petrelli JM, Rodriguez C, Heath CW. Body-mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999;341:1097-105.
20. Lee IM, Manson JE, Hennekens CH, Paffenbarger RS. Body weight and mortality: a 27-year follow-up of middle-aged men. JAMA 1993;270: 2823-8.
21. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999; 282:1523-9.
22. Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on co-morbid conditions. Obes Res 2001;9(suppl 4):326S-34S.
23. Vasan R, Pencina MJ, Cobain M, Freiberg MS, D'Agostino RB. Estimated risks for developing obesity in the Framingham Heart Study. Ann Intern Med 2005;143:473-80.
24. Anderson JW, Luan J, Hoie LH. Structured weight-loss programs: a meta-analysis of weight loss at 24 weeks and assessment of effects of intensity of intervention. Adv Ther 2004;21:61-75.
25. Landers S, Landers T. Survival analysis of dropout patterns in dieting clinical trials. J Am Diet Assoc 2004;104:1586-8.